MENU

Can Maximus (MMS) Stock Reach $100?

a provider of business process services to government health and human services agencies

A.I.Advisor
published price charts
A.I.Advisor
Nov 15, 2026

Can Maximus (MMS) Stock Reach $100?

Key Takeaways

  • The central target of $100 is the arithmetic mean of three current, attributable analyst price targets — BTIG at $100, Raymond James at $95, and Stifel at $102 — rounded to a clean level.
  • With shares of MMS near $64.71, reaching $100 would require a gain of roughly 55%, a very large move.
  • The verified target range is narrow, spanning about $95 to $102, although thin sell-side coverage means some aggregators show a wider band that includes older estimates.
  • Supporting factors include a low valuation (a trailing P/E near 9.6), strong free cash flow, aggressive buybacks, a rising dividend, and a steady flow of government contract wins.
  • Key risks are federal spending and budget-policy pressure, a divestiture that trimmed revenue guidance, and the fact that the stock has already retreated sharply from its $100 52-week high.
  • For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
  • Explore Trending AI Robots to see how AI-driven strategies are navigating current market conditions.

Analyst Price Targets and Consensus View

Maximus, Inc. (MMS) is a business process services provider that administers health and human services programs for governments. Coverage of the stock is unusually thin, with only a handful of active sell-side ratings. Reviewing current, attributable targets yields three: BTIG reiterated a Buy with a $100 target in July 2026; Raymond James (analyst Brian Gesuale) maintains an Outperform rating with a $95 target, raised from $90 in January 2026; and Stifel carries a $102 target. These three average roughly $99, which rounds to a central target of $100.

All three are constructive ratings, but that agreement partly reflects the small sample rather than a broad consensus. Because a couple of data aggregators include older or poorly attributed figures, reported ranges can vary widely — some show a $75-to-$110 band. Investors should treat the $100 figure as a calculated average of the current named targets, not as an official published consensus.

Current Market Position and Path Toward the Target

Shares of MMS closed near $64.71 in mid-November 2026, with a 52-week range of roughly $51 to $100. Reaching the $100 central target implies about 55% upside — a very large move. Notably, the stock already traded near that level within the past year, having touched a 52-week high around $100 before retreating roughly 35%. The path back to $100 therefore looks less like breaking into uncharted territory and more like reclaiming a prior high after a significant de-rating.

The company's fundamentals remain solid by valuation standards. Trailing twelve-month revenue is about $5.25 billion, net income roughly $371 million, and diluted EPS (earnings per share) near $6.76. The stock trades at a trailing P/E (price-to-earnings ratio) near 9.6 and a forward P/E near 7.8, well below the broader market. Management narrowed fiscal 2026 revenue guidance to roughly $5.2 billion to $5.35 billion, partly reflecting a divested U.S. services business, which has kept top-line expectations tempered even as profitability improves.

What Could Support a Move Toward the Target

  • Valuation. A single-digit forward P/E leaves room for multiple expansion if earnings visibility improves.
  • Capital returns. Maximus completed a large buyback program — repurchasing roughly 15% of shares outstanding — and raised its quarterly dividend 10% to $0.33 per share in January 2026.
  • Contract momentum. Recent awards include a U.S. Air Force cyber command contract, a Massachusetts Health Connector enrollment agreement, and a Pennsylvania enrollment-assistance renewal, supporting a durable revenue base.
  • Margin execution. Raymond James cited margin growth in raising its target, and EPS has grown faster than revenue in recent quarters.

What Could Prevent the Target From Being Reached

  • Federal budget and policy pressure. Government-services revenue is sensitive to spending priorities and efficiency initiatives, which can compress or delay contract awards.
  • Revenue headwinds. The divested U.S. services business trimmed guidance, and revenue is expected to decline modestly year over year in fiscal 2026.
  • Technical overhang. The stock's failure to hold near $100 and its subsequent slide suggest sellers have been active at elevated levels.
  • Thin coverage and liquidity risk. With few analysts and a small float, sentiment can shift quickly without a broad institutional consensus to anchor the stock.

Technical Levels and Market Structure

The $100 level is the most important reference point: it is both the psychological round number and the stock's 52-week high, acting as durable resistance. On the downside, the $51-to-$55 zone marks the 52-week low and a meaningful support area. The stock's roughly 35% decline from its high, combined with a beta below 1, indicates lower volatility than the broader market, but the distance back to $100 means any recovery would need sustained, multi-quarter confirmation rather than a single catalyst.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though the thin coverage here means individual timelines may differ. The most important near-term events are the fiscal fourth-quarter earnings report (scheduled around late November 2026), management's fiscal 2027 guidance, and any analyst target revisions that follow. Investors should also watch federal budget developments, new contract announcements, and continued progress on margins and buybacks.

AI Daily Buy/Sell Signals

For traders who want a more dynamic view than a static 12-month price target, Tickeron's AI Daily Buy/Sell Signals uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help users discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. For those following MMS, it offers a complementary, data-driven way to track momentum alongside fundamental research.

Final Assessment

The $100 central target is a calculated average of three current analyst targets — not a guarantee. It implies roughly 55% upside from the mid-$64 price, a very large move that would effectively reclaim the stock's 52-week high. The strongest supports are an inexpensive valuation, robust free cash flow, aggressive buybacks, dividend growth, and a healthy pipeline of government contracts. The principal obstacles are federal spending uncertainty, tempered revenue growth after a divestiture, and the stock's recent failure to hold elevated levels. With coverage thin and the range narrow, investors should focus on the upcoming earnings report, fiscal 2027 guidance, and any analyst revisions before drawing conclusions about the path toward $100.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement

MMS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MMS has been loosely correlated with ICFI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MMS jumps, then ICFI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MMS
1D Price
Change %
MMS100%
-5.00%
ICFI - MMS
44%
Loosely correlated
-1.94%
TRI - MMS
44%
Loosely correlated
-3.23%
BRC - MMS
42%
Loosely correlated
-1.98%
RELX - MMS
40%
Loosely correlated
-0.49%
BAH - MMS
39%
Loosely correlated
-1.67%
More

Groups containing MMS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MMS
1D Price
Change %
MMS100%
-5.00%
Office Equipment/Supplies
industry (45 stocks)
-2%
Poorly correlated
+196.02%
Producer Manufacturing
industry (346 stocks)
-4%
Poorly correlated
+20.74%